- AbbVie projects 2025 adjusted earnings per share (EPS) between $12.12 and $12.32, surpassing the estimate of $12.13.
- For the fourth quarter, AbbVie reported an adjusted EPS of $2.16, beating the estimate of $2.13.
- Net revenue for the fourth quarter was $15.10 billion, a 5.6% increase year-over-year, exceeding the estimate of $14.84 billion.
- Revenue from Humira was $1.68 billion, below the estimate of $1.93 billion.
- Skyrizi revenue reached $3.78 billion, surpassing the estimate of $3.57 billion.
- Rinvoq revenue was $1.83 billion, above the estimate of $1.71 billion.
- Imbruvica generated $848 million, exceeding the estimate of $802.2 million.
- Venclexta revenue was $655 million, falling short of the $668.6 million estimate.
- The Botox – Cosmetic segment earned $687 million, below the forecast of $764.4 million.
- Juvederm revenue was $279 million, under the expectation of $302.2 million.
- The Botox – Therapeutic segment made $873 million, closely matching the estimate of $873.5 million.
- Vraylar revenue reached $924 million, slightly under the estimate of $948.4 million.
- Ubrelvy revenue was $303 million, surpassing the $262 million estimate.
- Creon revenue amounted to $388 million, exceeding the forecast of $349.5 million.
- Adjusted research and development expenses were $2.27 billion, an 18% year-over-year increase, above the estimate of $2.07 billion.
- AbbVie maintains targets for a high single-digit compound annual revenue growth rate through 2029.
- The combined revenue projection for Skyrizi and Rinvoq in 2027 has increased to more than $31 billion, up from over $27 billion in previous guidance.
- AbbVie anticipates a high single-digit compound annual revenue growth rate for its aesthetics segment from 2025 to 2029.
- The firm expects overall net revenues to exceed their previous peak two years after the US Humira loss of exclusivity.
- Analyst recommendations include 19 buys and 10 holds, with no current sells.
Abbvie Inc on Smartkarma
Analyst coverage on AbbVie Inc. by top independent analysts on Smartkarma reveals bullish sentiments regarding the company’s performance and potential. Baptista Research‘s report titled “AbbVie Inc.: The SKYRIZI & RINVOQ Revolution: Capturing Market Share with Game-Changing Therapies! – Major Drivers” highlights AbbVie’s impressive third-quarter results for 2024. The company exceeded expectations with strong core growth driven by its ex-HUMIRA platform, achieving robust operational sales growth and surpassing sales forecasts. SKYRIZI and RINVOQ’s outstanding performance is projected to contribute significantly to AbbVie’s sales, surpassing initial expectations by $1.3 billion.
Another report by Baptista Research, titled “AbbVie Inc.: Recent Acquisitions & The Expansion of Immunology Portfolio Yielding Results? – Major Drivers,” emphasizes AbbVie’s solid financial performance in the second quarter of 2024 under the leadership of CEO Rob Michael. The company’s strategic acquisitions and expansion of its immunology portfolio have positioned it strongly in the biopharmaceutical industry. While AbbVie’s key products and pipeline developments show promise, analysts caution that various factors, including potential challenges, need to be considered for a comprehensive investment evaluation.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbvie Inc., a company focusing on pharmaceutical research and development, has received varying scores across different factors indicating its overall outlook. With a strong dividend score of 4, Abbvie is viewed positively in terms of its dividend payout to investors. The company also shows promise in terms of growth, with a score of 3, suggesting potential for expansion in the future. However, Abbvie’s value and resilience scores are relatively lower at 2 each, indicating some areas for improvement in terms of perceived value and resilience against market fluctuations. Momentum for Abbvie stands at 3, suggesting a moderate level of market momentum.
Overall, Abbvie Inc. is well positioned in the pharmaceutical industry with a diverse product portfolio catering to specialty therapeutic areas such as immunology, chronic kidney disease, oncology, and neuroscience. The company also provides treatments for a range of diseases including Parkinson’s and Alzheimer’s disease. Investors can consider Abbvie’s strong dividend score and growth potential in their long-term investment strategies, while keeping an eye on enhancing its value and resilience aspects to further solidify its position in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
